Lumicell’s Cancer Imaging Drug Faces Clinical Meaningfulness, Anaphylaxis Risk Questions At FDA Panel

 
• By Sarah Karlin-Smith
two people in operating room performing surgery
Lumicell hopes to help breast cancer patients avoid a second surgery with its medical imaging drug. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers